Basilea News http://www.basilea.com/ Basilea News en Thu, 27 Apr 2017 16:54:00 +0200 Thu, 27 Apr 2017 16:54:00 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections]]> http://www.basilea.com/News-and-Media/Basilea-announces-agreement-with-FDA-on-Special-Protocol-Assessments-for-antibiotic-ceftobiprole-phase-3-clinical-studies-in-bloodstream-and-skin-infections/39fff65b-c97a-73c1-d5e3-745f7e4e58bb
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
  • ]]>
    Fri, 21 Apr 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-agreement-with-FDA-on-Special-Protocol-Assessments-for-antibiotic-ceftobiprole-phase-3-clinical-studies-in-bloodstream-and-skin-infections/39fff65b-c97a-73c1-d5e3-745f7e4e58bb
    <![CDATA[Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab]]> http://www.basilea.com/News-and-Media/Data-presented-at-AACR-meeting-indicate-diverse-tumor-targeting-properties-of-Basileas-BAL101553-and-show-a-combination-potential-with-bevacizumab/94ede521-ce97-ea54-a9ac-84255d5b439f
  • BAL101553 targets tumor cell proliferation, adaptation to low oxygen and vascularization
  • Switch from weekly to daily oral dosing leads to reduced tumor anti-vascular activity while maintaining tumor growth inhibition
  • Combination with the anti-VEGF therapy bevacizumab shows enhanced anti-tumor response
  • ]]>
    Thu, 06 Apr 2017 07:15:00 +0200 http://www.basilea.com/News-and-Media/Data-presented-at-AACR-meeting-indicate-diverse-tumor-targeting-properties-of-Basileas-BAL101553-and-show-a-combination-potential-with-bevacizumab/94ede521-ce97-ea54-a9ac-84255d5b439f
    <![CDATA[Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors]]> http://www.basilea.com/News-and-Media/Basilea-proposes-Dr-Nicole-Onetto-as-new-member-of-the-Board-of-Directors/1abbab51-c0b7-1375-d0b7-2fb7ca87ca33 Mon, 27 Feb 2017 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-proposes-Dr-Nicole-Onetto-as-new-member-of-the-Board-of-Directors/1abbab51-c0b7-1375-d0b7-2fb7ca87ca33 <![CDATA[Basilea reports solid 2016 results and expects to double product sales in 2017]]> http://www.basilea.com/News-and-Media/Basilea-reports-solid-2016-results-and-expects-to-double-product-sales-in-2017/7b6a23bf-defd-715a-9a58-7b477474dd73
  • Cresemba® launched by Basilea in first European countries and marketed together with Zevtera®/Mabelio®
  • Entered into distribution and license agreements covering more than 40 countries for both Cresemba and Zevtera/Mabelio
  • Product sales of CHF 7.1 million in Europe and CHF 7.3 million royalties received on 2016 Cresemba US sales
  • CHF 289 million cash and financial investments at year-end
  • Initiation of ceftobiprole clinical phase 3 development program under BARDA agreement anticipated mid-2017 to support potential future US regulatory filing
  • ]]>
    Mon, 20 Feb 2017 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-solid-2016-results-and-expects-to-double-product-sales-in-2017/7b6a23bf-defd-715a-9a58-7b477474dd73
    <![CDATA[Basilea names new member of its Extended Management Committee]]> http://www.basilea.com/News-and-Media/Basilea-names-new-member-of-its-Extended-Management-Committee/8f2c4cd3-7cc1-089b-c2e9-2261759e9465 Thu, 29 Dec 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-names-new-member-of-its-Extended-Management-Committee/8f2c4cd3-7cc1-089b-c2e9-2261759e9465 <![CDATA[Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients]]> http://www.basilea.com/News-and-Media/Basilea-expands-oncology-drug-candidate-BAL101553-clinical-phase-1-2a-oral-study-to-include-glioblastoma-patients/1a527b22-cfe1-34ad-4424-a486019c0e51 Fri, 02 Dec 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-expands-oncology-drug-candidate-BAL101553-clinical-phase-1-2a-oral-study-to-include-glioblastoma-patients/1a527b22-cfe1-34ad-4424-a486019c0e51 <![CDATA[Basilea's antifungal Cresemba® (isavuconazole) launched in France]]> http://www.basilea.com/News-and-Media/Basileas-antifungal-Cresemba-isavuconazole-launched-in-France/d9d508c3-e54e-5016-6466-5ebaa5bc9937 Tue, 15 Nov 2016 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basileas-antifungal-Cresemba-isavuconazole-launched-in-France/d9d508c3-e54e-5016-6466-5ebaa5bc9937 <![CDATA[Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries]]> http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Unimedic-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-the-Nordic-countries/2950aecd-625d-561b-3949-6c299448a9ae Tue, 20 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-distribution-agreement-with-Unimedic-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-the-Nordic-countries/2950aecd-625d-561b-3949-6c299448a9ae <![CDATA[Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma]]> http://www.basilea.com/News-and-Media/Basilea-announces-partnership-for-antifungal-isavuconazole-in-Japan-with-Asahi-Kasei-Pharma/aa52f715-2c90-4c7d-1b8a-5aa0979184fb
  • Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan
  • Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties

  • ]]>
    Thu, 15 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-partnership-for-antifungal-isavuconazole-in-Japan-with-Asahi-Kasei-Pharma/aa52f715-2c90-4c7d-1b8a-5aa0979184fb
    <![CDATA[Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America]]> http://www.basilea.com/News-and-Media/Basilea-announces-supply-distribution-and-license-agreement-with-Grupo-Biotoscana-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-Latin-America/9cf5b991-223f-8e52-f0c6-d23cda71b4cb Tue, 13 Sep 2016 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-supply-distribution-and-license-agreement-with-Grupo-Biotoscana-for-CRESEMBA-isavuconazole-and-Zevtera-ceftobiprole-in-Latin-America/9cf5b991-223f-8e52-f0c6-d23cda71b4cb